VIM-2–producing Pseudomonas putida, Buenos Aires

To the Editor: Pseudomonas putida infections (0.03% of isolates from the culture collection of inpatients, SIR Program 2003–2004, www.aam.org.ar) are mainly reported in immunocompromised patients, such as newborns, neutropenic patients, and cancer patients. They are usually susceptible to extended-spectrum cephalosporins, aminoglycosides, fluoroquinolones, and carbapenems. However, isolates have been identified that produce acquired metallo-β-lactamases (MBLs) and are resistant to most β-lactams, including carbapenems.

Two multidrug-resistant P. putida isolates were obtained from clinical samples at the Sanatorio Mater Dei in Buenos Aires. One isolate was obtained in March 2005 from a urine specimen of a 76-year-old woman with a urinary tract infection who was using a urethral catheter. The second isolate was obtained in May 2005 from a tracheal aspirate of a 67-year-old man with nosocomial pneumonia.

Bacteria were identified by using conventional biochemical tests and the API 20NE System (API, bioMérieux, Lyon, France). Susceptibility tests were performed according to standard procedures. Both isolates were resistant to imipenem and meropenem (MICs >32 µg/mL) but were susceptible to amikacin and colistin. Susceptibility data are shown in the Table.

Screening for MBLs was performed by using a double-disk diffusion method. Disks containing 1 µmol EDTA (metal chelator) were placed on Mueller-Hinton agar plates containing the 2 isolates. Disks containing carbapenem were placed 15 mm from disks containing EDTA. An increase in the inhibition zone of the disk containing drug near the disk containing EDTA was observed for both isolates, which suggested the presence of MBLs.

PCR amplification of imp and vim genes was performed by using primers based on conserved regions of the imp and vim genes (blaIMP-F: 5′-GAAGGCCTTTATGTCATCCT-3′, blaIMP-R: 5′-GTTTGCCCATTACCATATTGGA-3′, blaVIMG-F: 5′-GGTTGGTGGCATATC-3′, and blaVIMG-R 5′-TGGGCCCATTCAGCAGATC-3′) and heat-extracted DNA as template. Reactions were performed in a T-gradient instrument (Biometra, Göttingen, Germany) with the following reaction conditions: 1 cycle at 95°C for 5 min, 52°C for 15 min, and 72°C for 6 min, followed by 30 cycles at 95°C for 1 min, 52°C for 1 min, and 72°C for 1 min, and a final reaction at 72°C for 20 min. Amplified fragments were sequenced on both strands by using an ABI Prism DNA 3700 (Applied Biosystems, Foster City, CA, USA), and nucleotide sequences were compared by using BLAST (National Center for Biotechnology Information, Bethesda, MD, USA, www.ncbi.nlm.nih.gov/Tools/). Nucleotide sequences were completely homologous to the vim-2 coding gene.

Two repetitive-element–based PCR (rep-PCR) assays (ERIC-PCR and REP-PCR) with primers REP-1 (5′-GCGCCTGCATCATGCGCC-3′), REP-2 (5′-GCACTTACAGCCCATTAC-3′), ERIC-1 (5′-CACTTGGGTCCTCATAAATTA-3′), and ERIC-2 (5′-AAAGTACATGCGTGGTG-3′) were used to characterize isolates. PCR conditions were 94°C for 2 min, 30 cycles at 94°C for 30 s, 50°C for 1 min, and 72°C for 4 min, and a final reaction at 72°C for 7 min. Banding patterns were visually analyzed after electrophoresis of samples. Variations in band intensity were not considered to indicate genetic differences. Banding patterns obtained by REP-PCR and ERIC-PCR assays were identical in both isolates (data not shown).

Among the MBLs acquired by P. putida, IMP-1 was reported by Senda et al. in Japan in 1996 (1) and later reported in Taiwan and Japan (2). IMP-12 was the first IMP MBL described in P. putida in Europe (3). VIM-1 in P. putida was first reported in Europe (4), and VIM-2 in P. putida was first reported in Taiwan, Republic of Korea, Japan, and France (5,6). Our isolates were resistant to aztreonam (MIC 64 µg/mL). However, carbapenem-susceptible P. putida had low

| Drug                  | MIC (µg/mL) |
|-----------------------|-------------|
|                       | Isolate 1   | Isolate 2   |
| Imipenem              | 32          | 64          |
| Meropenem             | 64          | 64          |
| Ertapenem             | 128         | 128         |
| Piperacillin          | 64          | 64          |
| Piperacillin-tazobactam | 32       | 32          |
| Cefazidime            | 128         | 128         |
| Cefepime              | 32          | 32          |
| Aztreonam             | 64          | 64          |
| Amikacin              | 4           | 4           |
| Gentamicin            | 16          | 16          |
| Ciprofloxacin         | >64         | >64         |
| Gatifloxacin          | >64         | >64         |
| Levofloxacin          | >64         | >64         |
| Moxifloxacin          | >64         | >64         |
| Doxycycline           | 64          | 64          |
| Colistin              | 2           | 2           |

668 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 4, April 2007
levels of susceptibility because the MIC$_{90}$ was only 1 dilution below the current breakpoint (7,8). Aztreonam resistance could not be transferred by conjugation between IMP-1–producing (aztreonam-resistant) *P. putida* and *P. aeruginosa* (2) and is not associated with a transposon carrying blaVIM-2 (6). No evidence of extended-spectrum β-lactamases was detected in our isolates by classic synergy assays with clavulanate plus aztreonam, ceftazidime, or cefotaxime. VIM-6–producing *P. putida* isolates from Singapore (9) were more resistant to aztreonam (MIC >128 µg/mL), ceftazidime, and cefotaxime. VIM-2 in *P. putida*–producing isolates from Venezuela. To the best of our knowledge, our report is the first of VIM-2 in *P. putida* in Latin America. VIM-2–producing *P. putida*, which were originally restricted to East Asia and only very recently found in France, may represent an emerging pathogen or function as reservoirs for resistance because of their widespread presence in the hospital environment.

Detection of bla$_{VIM-2}$ in *Pseudomonas* in South America was initially reported by the SENTRY Antimicrobial Surveillance Program (10) and included 1 *P. fluorescens* isolate in Chile and 3 *P. aeruginosa* isolates in Venezuela. To the best of our knowledge, our report is the first of VIM-2 in *P. putida* in Latin America. VIM-2–producing *P. putida*, which were originally restricted to East Asia and only very recently found in France, may represent an emerging pathogen or function as reservoirs for resistance because of their widespread presence in the hospital environment.

**References**

1. Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S, et al. PCR detection of metallo-β-lactamase gene (bla$_{VIM}$) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol. 1996;34:2990–9.
2. Yomoda S, Okubo T, Takahashi A, Murakami M, Iyobe S. Presence of *Pseudomonas putida* strains harboring plasmids bearing the metallo-β-lactamase gene bla$_{VIM}$ in a hospital in Japan. J Clin Microbiol. 2003;41:4246–51.
3. Docquer JD, Riccio ML, Mugaialoi C, Luzzaro F, Endimiani A, Toniolo A, et al. IMP-12, a new plasmid-encoded metallo-β-lactamase from a *Pseudomonas putida* clinical isolate. Antimicrob Agents Chemother. 2003;47:1522–8.
4. Lombardi G, Luzzaro F, Docquer JD, Riccio ML, Perilli M, Coli A, et al. Nosocomial infections caused by multiresistant isolated of *Pseudomonas putida* producing VIM-1 metallo-β-lactamase. J Clin Microbiol. 2002;40:4051–5.
5. Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM, et al. bla$_{VIM-2}$ Cassette-containing novel integrons in metallo-β-lactamase-producing *Pseudomonas aeruginosa* and *Pseudomonas putida* isolated disseminated in a Korean hospital. Antimicrob Agents Chemother. 2002;46:1053–8.
6. Poirel L, Cabanne L, Collet L, Nordman Y, Pugliese M, Lorenzo Barba F, Mattera J, et al. ‘In vitro’ activity of different antimicrobials agents on gram-negative nonfermentative bacilli, including *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. [in Spanish]. Rev Argent Microbiol. 2005;37:34–45.
7. Vay CA, Almuzara M, Rodriguez C, Pugliese M, Lorenzo Barba F, Mattera J, et al. ‘In vitro’ activity of different antimicrobial agents on gram-negative nonfermentative bacilli, excluding *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. [in Spanish]. Rev Argent Microbiol. 2005;37:34–45.
8. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-fermentative gram-negative bacilli. Int J Antimicrob Agents. 2005;25:95–109.
9. Koh TH, Wang GCY, Song LH. IMP-1 and a novel metallo-β-lactamase, VIM-6, in fluorescent pseudomonads isolated in Singapore. Antimicrob Agents Chemother. 2004;48:2334–6.
10. Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, Walsh TR, et al. First isolation of bla$_{VIM-2}$ in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2004;48:1433–4.

**Multidrug-resistant Acinetobacter baumannii, Russia**

To the Editor: During the past decade, nosocomial infections due to multidrug-resistant *Acinetobacter baumannii* have been described with increasing frequency, mostly in intensive care units (ICUs), resulting in therapeutic difficulties (1). The main mechanism for resistance to extended-spectrum cephalosporins in *A. baumannii* is attributed to the overexpression of chromosome-encoded cephalosporinases or to plasmid-encoded Ambler class A, B, and D β-lactamases (2). *A. baumannii* that produce PER-1 extended-spectrum β-lactamase (ESBL) are rarely isolated outside Turkey and remain susceptible to carbapenems (3). Here we describe what we believe is the first ESBL-producing *A. baumannii* isolate resistant to carbapenems and the first characterization of a PER-1 *A. baumannii* isolate from Russia, further supporting the emergence and dissemination of PER-1 *A. baumannii* strains in eastern Europe and outside Turkey (3,4).

On April 17, 2005, a 79-year-old man was hospitalized in the cardiology ward of a private hospital in Moscow, Russia, with cardiac arrhythmia and a pulmonary infarction subsequent to a pulmonary embolism. After 1 week, he was transferred to the ICU for multiple organ failure related to a nosocomial infection caused by an *A. baumannii* strain